Vertex Pharmaceuticals (VRTX)
Nasdaq · Boston, Massachusetts, USA · Founded 1989 · CEO Reshma Kewalramani
Valuation summary
$344.88 fair value versus $520.66 in the market, a difference of -33.8%. Rated Sell.
| Fair value per share | $344.88 |
| Current share price | $520.66 |
| Upside / downside | -33.8% |
| Bear case | $252.95 |
| Bull case | $473.64 |
| Discount rate (WACC) | 9.4% |
| Terminal growth | 3.00% |
| Market capitalisation | $132B |
| EV / Sales | 9.4x |
About Vertex Pharmaceuticals
Founded in 1989 by Joshua Boger in Cambridge, Massachusetts, with a then-radical commitment to structure-based rational drug design. Reshma Kewalramani has been CEO since 2020. Vertex effectively owns the cystic fibrosis market with Trikafta and its successor Alyftrek, treating the underlying protein defect rather than symptoms. It has diversified into Casgevy, the first approved CRISPR gene-editing therapy, developed with CRISPR Therapeutics for sickle cell disease, and Journavx, a non-opioid painkiller approved in 2025 for acute pain. In September 2026 it completed the roughly $10B acquisition of Crinetics Pharmaceuticals, adding Palsonify for acromegaly and atumelnant, in development for congenital adrenal hyperplasia and Cushing's syndrome, as a rare endocrine franchise.
Investment case
- A near-monopoly in cystic fibrosis with pricing power and patients who stay on therapy for life.
- Journavx addresses acute pain without opioid addiction risk, which is a very large market with obvious policy support.
- Large net cash position funds development without dilution.
Key risks
- Extreme concentration — cystic fibrosis is the overwhelming majority of revenue.
- Casgevy uptake has been slow because the treatment process is complex and expensive to administer.
- Cystic fibrosis patent protection eventually erodes and the diversification has to work before then.
Recent developments
- 2026-09-08 · Goldman Sachs added Vertex to its conviction list. source
- 2026-09-01 · Vertex completed its Crinetics acquisition (about $10B equity value, $8.8B net of cash), adding acromegaly drug Palsonify and atumelnant. source
- 2026-08-04 · Q2 revenue $3.33B, up 12%, non-GAAP EPS $4.73; 2026 revenue guidance raised to $13.1-13.2B from $12.95-13.1B; Journavx $49.6M, Casgevy $76.4M. source
Revenue by segment
| Cystic Fibrosis | 84% |
| Pain, Gene Therapy & Other | 16% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $14.2B | $3.8B |
| Year 2 | $15.7B | $4.1B |
| Year 3 | $17.2B | $4.3B |
| Year 4 | $18.9B | $4.6B |
| Year 5 | $20.7B | $4.9B |
What the street says
Respected for scientific execution. Management calls rare endocrine disease, added through the Crinetics acquisition, a new commercial pillar, and the debate is whether these newer businesses can become material before the core cystic fibrosis franchise matures.
Comparable companies: REGN · NVO · EW · GILD · ABT · AMGN · DHR · ISRG
Open the interactive model, price chart and sensitivity grid →